Evidence map›Paper›PMID 29027222›Full record

ReviewImmunological reviews2017

Alarmins and immunity.

De Yang, Zhen Han, Joost J Oppenheim

Open access · greenAbstract readReview
In one paragraph

Review in Immunological reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 262 papers.

0numbers the graph read from it
0cells of the map it votes in
262citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

262 citing papers in PubMed, 384 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Cleavage-Resistant CYLD Protects Against Autoimmune Hepatitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  14. A requirement formSphere · 2026
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

202 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

De YangCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, USA.
Zhen HanCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, USA.
Joost J OppenheimCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, USA.ORCID 0000-0003-0271-7921
National Institutes of Health · US

Funding

Studies of Receptor Interactions and Effects of AlarminsZIABC009369 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OPPENHEIM, JOOST J · 2009 to 2022
$16.5M
Studies of Chemokine-Receptor Interactions with Chemokines and alarminsZ01BC009369 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OPPENHEIM, JOOST J · 1996 to 2008
$1.8M
Intramural NIH HHS Z01 BC009369Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

More than a decade has passed since the conceptualization of the "alarmin" hypothesis. The alarmin family has been expanding in terms of both number and the concept. It has recently become clear that alarmins play important roles as initiators and participants in a diverse range of physiological and pathophysiological processes such as host defense, regulation of gene expression, cellular homeostasis, wound healing, inflammation, allergy, autoimmunity, and oncogenesis. Here, we provide a general view on the participation of alarmins in the induction of innate and adaptive immune responses, as well as their contribution to tumor immunity.

Indexed as

ImmunityAlarminsAnimalsAutoimmunityCarcinogenesisGene Expression RegulationHomeostasisHumansNeoplasmsWound HealingAlarminsalarmindamage-associated molecular patterndendritic cellsimmune responsetumor immunity

Identifiers

PMID29027222
PMCPMC5699517
OpenAlexW2761905894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.